Fed’s Collins says PCE does not change restrictive policy view
The Boston Fed President, Suan Collins, crossed the wires on Thursday as the Jackson Hole Symposium began. She said that the recent PCE report does not change the view that policy is restrictive and will lead to gradual disinflation.
Collins added that the jump in US bond yields is “still consistent with price stability,” and added that she has no comment on Bessent’s intervention.
Recently, Collins added via an interview with the Wall Street Journal that a rate hike is warranted if inflation disappoints.
Key highlights:
RECENT PERSONAL CONSUMPTION EXPENDITURES REPORT DID NOT CHANGE MODAL OUTLOOK THAT CURRENT MONETARY POLICY IS RESTRICTIVE AND WILL LEAD TO A GRADUAL DISINFLATION
PORTFOLIO MANAGEMENT FEES HAD AN OUTSIZED INFLUENCE ON HEADLINE INFLATION, WITH MARKET-BASED PRICES MORE IN LINE WITH FED'S TARGET
RECENT INFLATION DATA 'MIXED,' WITH HEADLINE FIGURE STRONGER THAN EXPECTED BUT 'PROMISING SIGNS' IN THE DETAILS
RECENT INCREASE IN BOND YIELDS STILL CONSISTENT WITH PRICE STABILITY, NOT A SIGN INFLATION EXPECTATIONS ARE INCREASING
ABSENT NEW TARIFF AND OIL SHOCKS, THERE ARE REASONS TO THINK INFLATION WILL EASE
SHE IS WATCHING BOND YIELDS, BUT HAS NO COMMENT ON BESSENT'S INTERVENTION
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cambria Gold Mines FY26 Q2 net loss narrows to CAD 2.96 million
TRUMP rises nearly 8% in 24 hours, market capitalization reaches $2.037 billions
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

